Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
60,972,167
-
Share change
-
-2,265,273
-
Total reported value
-
$2,275,287,745
-
Put/Call ratio
-
78%
-
Price per share
-
$37.32
-
Number of holders
-
200
-
Value change
-
-$67,012,413
-
Number of buys
-
102
-
Number of sells
-
86
Institutional Holders of DICERNA PHARMACEUTICALS INC - COM (DRNA) as of Q2 2021
As of 30 Jun 2021,
DICERNA PHARMACEUTICALS INC - COM (DRNA) was held by
200 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
60,972,167 shares.
The largest 10 holders included
RTW INVESTMENTS, LP, BlackRock Inc., VANGUARD GROUP INC, WELLINGTON MANAGEMENT GROUP LLP, Bain Capital Life Sciences Investors, LLC, STATE STREET CORP, PRICE T ROWE ASSOCIATES INC /MD/, Aquilo Capital Management, LLC, LOOMIS SAYLES & CO L P, and JPMORGAN CHASE & CO.
This page lists
200
institutional shareholders reporting positions in this security
for the Q2 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.